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Highlights 
 Epigenetic modifications play a role in neurodevelopment. 
 Few epigenetic markers have been repeatedly identified in relation to ASD or ADHD.  
 Suboptimal designs and heterogeneity hamper the interpretation of findings. 
 Large hypothesis-free studies can provide insight into the epigenetics of ASD/ADHD. 
 
 
 
ABSTRACT 
Epigenetic processes have been suggested as key mechanisms in the etiology of neurodevelopmental 
disorders. This systematic review summarizes the current evidence for an association between epigenetics 
and Autism Spectrum Disorder (ASD) and Attention/Deficit-Hyperactivity Disorder (ADHD). Six 
databases were searched until the 24th of October 2017. Of the 2169 retrieved articles, 29 met our 
inclusion criteria. While generally associations between epigenetics and neurodevelopmental disorders 
were reported, only a few findings were consistent across independent analyses. Differential epigenetic 
markers were repeatedly identified in OR2L13, C11orf21/TSPAN32, PRRT1 and H3K27 for autism, and in 
VIPR2 for ADHD. Overall, evidence of an association between epigenetic modifications and ASD or 
ADHD should be considered preliminary and based on studies suffering from numerous caveats. We 
highlight the need for carefully designed investigations and for greater homogeneity and provide specific 
recommendations for future research. Despite our current limited understanding, the suggestive findings 
and the rapid advances in the field hold the promise of a forthcoming elucidation of the role of epigenetic 
modifications in neurodevelopmental disorders.  
Key Words: ASD; ADHD; DNA methylation; histone modifications; epigenetics.  
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1. INTRODUCTION 
Neurodevelopmental disorders are psychiatric conditions arising in early life featuring abnormalities in the 
central nervous system development. These can lead to emotional and behavioral problems and 
impairments in psychological, social, academic and occupational functioning (American Psychiatric 
Association, 2013). Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder 
(ADHD) are among the most common and well-known neurodevelopmental conditions, afflicting about 
1% and 5% of children, respectively (American Psychiatric Association, 2013). A rise in the prevalence 
rates of these conditions has recently been reported (American Psychiatric Association, 2013; Boyle et al., 
2011), highlighting the need for careful explorations of pathways to disorder etiology; although higher 
rates might result from confounding factors such as increased disorder awareness and methodological 
issues (American Psychiatric Association, 2013; Polanczyk et al., 2014).  
ASD is characterized by restricted and repetitive behaviors and impairments in social interaction 
and communication. Autism is currently conceptualized as a spectrum of disorders capturing the 
commonalities across previously identified subtypes (e.g. Asperger’s Disorder, Autistic Disorder) while 
allowing for heterogeneity within this condition (American Psychiatric Association, 2013). For instance, 
individuals requiring very substantial support as well as highly functioning persons can meet the criteria 
for this disorder. ADHD is defined by hyperactivity, impulsivity, inattention and difficulties in 
organization atypical for the age of the child. Individuals suffering from ADHD can exhibit clinical 
hyperactivity/impulsivity and inattention (combined presentation) or the predominance of either of these 
symptoms (predominantly inattentive presentation, predominantly hyperactive/impulsive presentation) 
(American Psychiatric Association, 2013).  
Both neurodevelopmental disorders tend to persist into adulthood and can often co-occur, with the 
manifestation of ADHD symptoms in 30% to 50% of autistic patients (Leyfer et al., 2006; Lichtenstein et 
AC
CE
PT
ED
MA
NU
SC
RI
PT
4 
 
al., 2010; Taurines et al., 2012). The etiology of neurodevelopmental disorders is complex and involves 
multiple determinants. A substantial genetic component is present in both psychiatric conditions 
(American Psychiatric Association, 2013; Elia et al., 2012; Faraone et al., 2005; Loke et al., 2015; 
Tordjman et al., 2014). Furthermore, environmental factors, such as prenatal maternal stress and exposure 
to toxins, play a considerable role (American Psychiatric Association, 2013; Kubota and Mochizuki, 2016; 
Loke et al., 2015; Schuch et al., 2015); however, the processes through which the environment, by 
interacting with genetic susceptibilities, leads to the development of neurodevelopmental disorders are yet 
to be elucidated (Keil and Lein, 2016).  
Epigenetic modifications have been suggested as the mechanisms responsible for the biological 
encoding of environmental influences, representing the meeting point of genes and environment (Feil and 
Fraga, 2012; Keil and Lein, 2016; LaSalle, 2013; Latham et al., 2012). Epigenetic processes can regulate 
gene expression, without affecting underlying DNA sequences (Feil and Fraga, 2012). While there is 
growing evidence that epigenetic processes are sensitive to numerous environmental exposures (e.g. 
nutritional factors) (Feil and Fraga, 2012), the effect of genetic variation on epigenetic markers has also 
been documented (Kilpinen and Dermitzakis, 2012). Regardless of their determinant, epigenetic 
modifications are considered relevant factors in the etiology of complex disorders such as ASD and 
ADHD, which could account for the unexplained variance of disorder occurrence.  
The most studied epigenetic changes are DNA methylation and histone modifications. The former 
occurs when a methyl group is added to specific DNA base pairs, primarily in the context of cytosine-
guanine dinucleotides (CpGs). Methyl groups regulate gene expression determining activation or 
inhibition of activity, according to the methylated location (e.g. gene body, CpG island) (Moore et al., 
2013) and to the degree of DNA methylation, typically expressed as hypomethylation (i.e. lower levels of 
DNA methylation) or hypermethylation (i.e. higher levels of DNA methylation). The three most common 
approaches to profile DNA methylation patterns are global, epigenome-wide and candidate gene DNA 
methylation analyses. Global DNA methylation provides an average estimate of DNA methylation levels 
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in the analyzed tissue sample by quantifying the methylcytosine (5-mC) present in the genome (Non and 
Thayer, 2015). In contrast, candidate gene DNA methylation studies and Epigenome-Wide Association 
Studies (EWAS) examine DNA methylation at specific CpG sites or regions and are thus defined as site-
specific studies. More precisely, EWAS are typically hypothesis-free and screen up to hundreds of 
thousands of loci across the genome to identify CpGs or regions associated with the disorder of interest. In 
contrast, candidate gene DNA methylation analyses target loci in one or a limited number of specific 
genes, based on a priori hypotheses.  
Post-translational histone modifications are a group of epigenetic alterations (e.g. lysine 
methylation and histone acetylation) which remodel chromatin structure and which are associated with 
variations in DNA expression (Bannister and Kouzarides, 2011). Histone acetylation is consistently 
related to transcriptional activation (Kouzarides, 2007), whereas the transcriptional consequences of 
methylation are determined by the position of such modification. For instance, while methylation in 
histone three lysine four (H3K4) is involved in activation of DNA expression, methylation in histone three 
lysine 27 (H3K27) is implicated in repression.  
Multiple publications have provided evidence of differential DNA methylation between cases and 
controls in ASD and ADHD (Loke et al., 2015; Walton et al., 2017) and of histone modifications in 
patients with ASD only (Sun et al., 2016). However, a comprehensive assessment of the epigenetic 
modifications present in both neurodevelopmental disorders is currently lacking. Therefore, the aim of this 
systematic review is to identify, integrate and discuss all available evidence on the association of DNA 
methylation and histone modifications with ASD and ADHD.  
 
2. MATERIALS AND METHODS 
2.1 Literature Search  
In order to conduct this review, we followed a predefined protocol adhering to the PRISMA and MOOSE 
guidelines (Appendices 1 and 2). The search of six bibliographic databases (Embase.com, Web-of-
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Science, Medline (Ovid), Cochrane Central, PsycINFO Ovid and Google Scholar) was performed on 
January 12th 2017 and updated on October 24th 2017 (last data search), in collaboration with a medical 
information specialist. The searched terms referred to both exposure (e.g. epigenetics, histone, DNA 
methylation, CpG) and outcomes (e.g. neurodevelopmental disorders, ASD, ADHD). We limited the 
search to studies on humans, but no language, tissue type (in vivo or post-mortem) or publication date 
restrictions were applied. The complete search strategies can be found in Appendix 3. To retrieve further 
relevant publications, we consulted experts and examined literature reviews on the topic.  
2.2 Study Selection and Inclusion Criteria 
Studies were included if they described the association between epigenetic marks (DNA methylation or 
histone modifications) and ASD or ADHD. The excluded studies (i) referred to epigenetic marks different 
from histone modifications and DNA methylation; (ii) examined neurodevelopmental disorders other than 
ASD and ADHD, such as Down Syndrome, Fetal Alcohol Spectrum Disorder and Intellectual Disability; 
(iii) were not empirical studies; (iv) did not compare cases to controls. Psychiatric disorders other than 
ASD and ADHD were excluded in order to limit the scope of our systematic review to two of the most 
common and comorbid forms of neurodevelopmental conditions. Additionally, the traits (e.g. high 
negative affect) and etiological factors shared by ASD and ADHD (Visser et al., 2016) point to the 
possibility of similar biological profiles. Other disorders of neurodevelopmental etiology, such as 
schizophrenia, have been reviewed elsewhere (Fullard et al., 2016; Homberg et al., 2016; van Bokhoven, 
2011). Two independent reviewers selected the publications meeting the inclusion criteria by examining 
titles and abstracts. In case of disagreement a senior researcher was available, but all divergences 
regarding the chosen articles were discussed and solved between the two reviewers. Full texts of the 
studies of interest were retrieved and a further selection was performed according to the inclusion and 
exclusion criteria.  
2.3 Data Extraction 
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The relevant information from the studies was collected in predesigned data forms, which varied 
according to the type of approach (global, candidate gene, epigenome-wide DNA methylation and histone 
modifications) and which were subdivided by tissue examined (brain tissue or peripheral – other tissues 
such as blood and saliva-). These data forms included the neurodevelopmental disorder outcome (ASD or 
ADHD), sample size (cases/controls), sample characteristics (population, age range or mean age and sex), 
tissue type, the methodology for epigenetic marks assessment (type of statistical analysis and platform), 
the presence of validation or replication, adjustments or matching and a summary of the findings with 
reported statistics (e.g. p-values) (Tables 1-6). Of note, validation refers to the verification of findings in 
the same sample with the use of a different methodology. Replication instead entails testing a new group 
of participants.  
When the required information was not presented in the included articles, we contacted 
correspondence authors. If there was no response, we classified the missing information as “not available” 
(NA).  Data extraction was performed by one author, who was assisted by a research analyst in the 
identification of platforms used.  
2.4 Assessing the Risk of Bias 
Although PRISMA and MOOSE guidelines require quality assessment of the included studies, we decided 
not to perform a formal evaluation due to the lack of specific guidelines for epigenetic studies (e.g. 
required sample size according to approach, platform coverage, performance of validation).  
2.5 Outcome Assessment and Statistical Methods 
For each study, we defined whether an association was present and, when applicable, effect sizes were 
reported. We sought to pool the results using a random effects meta-analysis model. However, due to high 
heterogeneity in the input parameters, assumptions and study design, it was not feasible to perform 
quantitative pooling of the existing data.  
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
3. RESULTS 
As shown in Figure 1, through a literature search and other sources, we identified 2169 potentially 
relevant articles. Of these, 29 met the eligibility criteria and were thus included in this review. Reasons for 
exclusion of individual articles can be disclosed upon request. In the following section, we provide a 
summary of all included studies, followed by a review of their findings. Results are presented for each 
neurodevelopmental disorder separately and further subdivided according to the approach employed 
(global DNA methylation, candidate gene DNA methylation studies, EWAS and histone modifications) 
and tissue examined (brain, peripheral). 
3.1 Summary of included studies  
Overall, ASD was examined in 24 publications (global DNA methylation, candidate genes, EWAS and 
histone modifications) and ADHD in five (candidate genes and EWAS). No study focused on epigenetic 
marks in both disorders.  
Cross-sectional designs comparing cases and controls were commonly used (n=24). A few 
publications examined participants prospectively in nested case-control studies (Schroeder et al., 2016; 
Van Mil et al., 2014; Walton et al., 2017) or compared monozygotic twins discordant for the disorder of 
interest (Nguyen et al., 2010; Wong et al., 2014). Of the included studies, 11 sampled individuals in the 
USA, three in China and two in the UK. The remaining studies were from Spain, Croatia, Italy, The 
Netherlands, comprised multiple samples of participants from mixed countries, or, did not specify the 
sample nationality. The selected publications mainly included individuals with mixed age at epigenetic 
assessment (n=15). Other articles sampled the tissues of the participants during the neonatal period (n=3), 
childhood (n=5) or adolescence (n=1). Of these, Walton et al. (2017) assessed epigenetic marks at 
multiple time points during the neonatal period and childhood.  No study targeted an adult population 
only, while six publications did not disclose the patients’ age. Regarding tissue sampling, 17 studies 
analyzed peripheral tissue (blood, lymphoblastoid cell lines, leucocytes, cord blood, buccal epithelium, 
placenta, and saliva) while12 used post-mortem brain tissue (cerebellum, cortices - temporal, occipital, 
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(pre)frontal cortex -, pons, Brodmann’s areas and fusiform gyrus). The most commonly examined tissues 
were blood and cerebellum.  
The majority of the publications used a candidate gene (n=14) or EWAS (n=14) approach to test 
the presence of differential epigenetic marks. Few studies only quantified global DNA methylation (n=5) 
or histone modifications (n=2). Five publications employed multiple approaches to epigenetic analysis as 
shown in Supplementary Table S1. Different methods were used to assess global DNA methylation status 
(e.g. HPLC tandem mass spectrometry (LC-MS/MS)). The included site-specific methylation studies 
mainly examined differentially methylated positions (DMP) or differentially methylated regions (DMR). 
Most of the candidate gene DNA methylation studies used bisulfite pyrosequencing, a quantitative 
approach with high reproducibility, but with relatively short length of reads (Non and Thayer, 2015). The 
most commonly used platform in epigenome-wide analyses was the Illumina Infinium 
HumanMethylation450K BeadChip (Infinium (HM)450K array)), which allows for the screening of over 
450’000 CpG sites with high quantitative accuracy (Non and Thayer, 2015). The platform covers 
approximately 2% of all human CpG sites and underrepresents several genomic components such as 
enhancer regions (Barker et al., 2017). Of the 14 EWAS, four included an independent sample to confirm 
the findings from the discovery analysis (Aldinger et al., 2013; Homs et al., 2016; Ladd-Acosta et al., 
2014; Wilmot et al., 2016), while ten validated their results using an independent approach in the same 
cluster of participants (e.g. Berko et al., 2014; Nardone et al., 2017). Of the candidate gene DNA 
methylation studies, only one study conducted a validation analysis (Jiang et al., 2004). Adjustments or 
matching for age or sex were generally performed. A few studies controlled for additional covariates such 
as batch effects, cell heterogeneity, and post-mortem brain interval. More information on the 
characteristics of the included publications can be found in Tables 1-6. 
3.2 Autism Spectrum Disorder  
3.2.1 Global DNA Methylation 
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Global DNA methylation status of autistic patients and controls was compared in five publications, two 
focusing on brain and three on peripheral tissue. Characteristics and findings of global DNA methylation 
studies investigating ASD are available in Table 1. 
Brain Tissue: No consistent associations between global DNA methylation and autism were 
identified by two independent studies in brain tissue. James et al. (2013) detected statistically significant 
DNA hypermethylation through Tandem Mass Spectrometry (LC/MS/MS) in the cerebellum of 13 autistic 
subjects when compared to 13 controls of mixed age (M ± SD = 5.9±1.2 in cases, 4.7±1.1 in controls). 
Contrasting results were reported by Mitchell et al. (2012), who did not find proof for significant global 
DNA methylation differences in LINE-1 elements in Brodmann’s area 19 of 12 cases and 12 controls of 
mixed age. 
Peripheral Tissue:  No consistent associations of global DNA methylation with autism were 
reported by three independent studies in peripheral tissue. Two articles did not find evidence for 
differences in whole blood, placenta and cord blood of children up to 15 years by employing MethylC-
sequencing and Luminometric Methylation Assay (LUMA) (Schroeder et al., 2016; Wong et al., 2014). 
Tsang et al. (2016), who used restriction enzymes for their research, found DNA hypermethylation in the 
leucocytes of 280 autistic five-year-old children (∆β = 54.35±21.37).  
3.2.2 Epigenome-Wide DNA Methylation 
The association between genome-wide DNA methylation and ASD was examined in 12 studies, five 
focusing on brain and seven on peripheral tissue. Characteristics and findings of the included epigenome-
wide analyses investigating ASD can be found in Table 2. 
Brain Tissue: Associations between differential DNA methylation and autism in a genomic area 
encompassing Chromosome 11 open reading frame 21 (C11orf21) and Tetraspanin 32 (TSPAN32) were 
found by three independent analyses (Ladd-Acosta et al., 2014; Nardone et al., 2014). Ladd-Acosta et al. 
(2014) sampled the cerebellum and temporal and prefrontal cortices of 20 cases and 21 controls in a 
genome-wide significant regional change analysis. They reported DNA hypomethylation of 
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C11orf21/TSPAN32 (∆M = -6.6%) in the temporal cortex and replicated their findings in different brain 
regions (cerebellum and pre-frontal cortex) within the same genomic region. Consistent with these results, 
Nardone et al. (2014) showed differential DNA methylation of C11orf21/TSPAN32 in Brodmann’s area 
10 between 12 cases and 12 controls of mixed age and validated this finding (∆β = 0.39 to -4.93). 
Associations in Proline Rich Transmembrane Protein 1 (PRRT1) were consistently identified by three 
analyses. Ladd-Acosta et al. (2014) reported DNA hypomethylation of regions in PRRT1, both in the 
discovery (∆M = -7.8%) and replication samples. Nardone et al. (2014) additionally found differential 
DNA methylation in CpGs in PRRT1. 
Other findings of  differential DNA methylation were identified in sites/regions in, or near, 
SNORD family genes in frontal and temporal cortices and cerebellum (Feinberg et al., 2015),  ZFP57 (∆M 
= 13.9%), SDHAP3 (∆M = 15.8%) in prefrontal and temporal cortices and cerebellum (Ladd-Acosta et 
al., 2014), HDAC4, C1qA, IRF8 and CTSZ in Brodmann’s areas 10 and 24 (Nardone et al., 2014), 
GABBR1, ABAT, Mir124-1, Mir124-2, FAM124B, InNEAT1 in prefrontal cortex, Brodmann’s areas 10 
and 24 (Nardone et al., 2017). Of these, C1qA (∆β = -3.45), IRF8 (∆β = -3.42) and CTSZ (∆β = -2.13 to -
3.39) (Nardone et al., 2014), GABBR1 and Mir124-2, FAM124B and InNEAT1 (Nardone et al., 2017) were 
validated. An epigenome-wide analysis of Brodmann’s area 19, occipital and cerebellar cortices found no 
evidence for differences in DNA methylation between cases and controls of mixed age (Ginsberg et al., 
2012). 
Peripheral tissue: Associations between differential DNA methylation and autism in Olfactory 
Receptor family 2 subfamily L member 13 (OR2L13) – a gene involved in the neuronal response to 
odorants - were found by two independent studies sampling peripheral tissue (Berko et al., 2014; Wong et 
al., 2014). Berko et al. (2014) reported differential DNA methylation between 47 cases and 48 controls in 
buccal tissue in a cross-sectional study comprised of participants of mixed age (β = -8.0%). Wong et al. 
(2014), in a longitudinal analysis from birth till age 15, found differential DNA methylation of OR2L13 
between 66 cases and 44 controls in whole blood (∆β = 0.18); this finding was validated. Differentially 
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methylated markers in ENO2 – a gene coding for an isoenzyme present in mature neurons -  were partially 
identified by two independent analyses carried out by Wang et al. (2014). In their discovery cohort, they 
showed DNA methylation differences in 228 gene promoters and 247 CpG islands, including the ENO2 
promoter region, between 5 autistic children and 5 controls ranging from three to twelve years in venous 
blood. In their replication sample, they confirmed hypermethylation in correspondence to the ENO2 
promoter in 15% of a sample comprising 131 pairs of cases and controls (M = 39.1% in cases, M = 
18.81% in controls).   
Other publications reported the presence of contrasting epigenetic patterns between cases and controls in 
or near the following genes: TAC1, PTCD2, HOXA11, TCN1, ETNK2, SPAG7, FLJ44881 (|∆β| > 0.15) 
(Aldinger et al., 2013), BCL2 (M = 25% in cases, M = 9.5% in controls) and RORA in lymphoblastoid cell 
lines (Nguyen et al., 2010), DLL1 and LOC15444 in placenta (Schroeder et al., 2016), PIK3C3 (∆β = -
0.04), NFYC, C14orf152 (∆β = -0.16) and MGC3207 (∆β = -0.24) in blood (Wong et al., 2014), PAX8 (β 
= -7.5%), GPC1 (β = -8.6%), ADRA2C (β = -11.9%), FAM134B (β = -7.8%), CREB5 (β = 7.6%), NOS1 (β 
= 8.6%), MAPK8IP3 (β = 9%), HOOK2 (β = -7.9%), NRG2 (β = 7.6%), KCNQ5 (β = 7.7%), ZG16B (β = 
10.1%), LOC643802 (β = -8.9%) in buccal tissue (Berko et al., 2014). Of these, BCL2, RORA (Nguyen et 
al., 2010), DLL1 (Schroeder et al., 2016), TAC1(Aldinger et al., 2013), and MGC3207 (r = 0.91) (Wong et 
al., 2014) were validated. Only one study did not find evidence for differential DNA methylation patterns 
between cases and controls of mixed age in blood tissue (Homs et al., 2016). However, the authors did 
report epigenetic differences in 700 CpG sites when each individual patient was compared to ten controls; 
17 of these sites were replicated. 
3.2.3 Candidate Gene DNA Methylation  
The relation between DNA methylation and ASD was examined in 11 candidate gene DNA methylation 
studies collectively spanning 16 genes, 2 of which (MeCP2 and UBE3A) were selected by multiple 
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authors. Seven publications investigated brain tissue while four examined peripheral tissue. Characteristics 
and findings of all candidate gene DNA methylation studies examining ASD can be found in Table 3. 
Brain Tissue: Associations in MeCP2 – a gene coding for a protein with a methyl-CpG binding 
domain ([dataset] Geer et al., 2010) - were examined by three studies in mixed-age samples but could not 
be replicated. Nagarajan et al. (2006) reported DNA hypermethylation in autistic patients in MeCP2 
region I in Brodmann’s area 9 and in fusiform gyrus tissue. In a subsequent study, the same author showed 
no proof for statistically significant differences in region II of MeCP2 in Brodmann’s area 9 (Nagarajan et 
al., 2008). Ginsberg et al. (2012) reported no evidence for DNA methylation differences in MeCP2 in 
Brodmann’s area 19, occipital cortex and cerebellar hemispheric cortex, but they did not specify which 
genetic region was analyzed.  
Other studies found differential DNA methylation distribution in autistic subjects of mixed age in 
the RELN promoter region within Brodmann’s areas 41/42 and 22 (M ± SD = 29.55 ± 13.09 in cases, 5.70 
± 2.90 in controls) (Lintas et al., 2016) and higher DNA methylation in the EN-2 gene within the 
cerebellum (M ± SD = 23±4% to 38±7% in cases, 10±2% to 15±5% in controls) (James et al., 2013). A 
replication was not attempted. No proof for significant differences was found in correspondence to RORA, 
BCL2 and OXTR in Brodmann’s area 19 and cerebellar hemispheric cortices (Ginsberg et al., 2012), 
UBE3A in Brodmann’s area 19, cortices and cerebellum (Ginsberg et al., 2012; Jiang et al., 2004), SNRPN 
in cerebellum and cerebral cortex (Jiang et al., 2004), and OCA2 in Brodmann’s area 19 (Mitchell et al., 
2012).  
Peripheral Tissue: There was no attempt to replicate findings in candidate gene DNA methylation 
studies comparing autistic patients and controls in peripheral tissue. Hranilovic et al. (2016) found higher 
DNA methylation in autistic subjects of mixed age in a region of HTR2A – a gene encoding a receptor for 
serotonin ([dataset] Geer et al., 2010) - in the leukocytes of AG genotype carriers only. No evidence for 
significant differences was found in correspondence to FOXK1 in blood (Atsem et al., 2016), PEG1 and 
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COPG2 in leucocytes (Bonora et al., 2002) and PEG13, KCNK9 and TRAPPC9 in peripheral blood 
(Delgado et al., 2014). 
3.2.4 Histone Modifications  
The association between histone modifications and ASD was assessed by two studies in the brain tissue of 
mixed age populations (James et al., 2013; Sun et al., 2016). They analyzed different histone 
modifications (methylation and acetylation) on H3K27. James et al. (2013) reported lower trimethylation 
levels of H3K27 in the cerebellum of 11 autistic patients when compared to 11 controls. Consistently, Sun 
et al. (2016) found differential acetylation of H3K27 between 45 cases and 49 controls in the cerebellum, 
prefrontal and temporal cortices. No evidence for H3K4 to be differentially trymethylated was found in 
the cerebella of cases and controls (James et al., 2013). Further information regarding the studies 
examining histone modifications can be found in Table 4.  
3.3 Attention-Deficit/Hyperactivity Disorder 
The relation between epigenetic modifications and ADHD was investigated with the use of epigenome-
wide and candidate gene approaches only.  
3.3.1 Epigenome-Wide DNA Methylation  
The relation between ADHD and epigenome-wide DNA methylation was examined by two studies 
(Walton et al., 2017; Wilmot et al., 2016) and in peripheral tissue only. Differential DNA methylation in 
Vasoactive Intestinal Peptide Receptor 2 (VIPR2) was found in two independent analyses carried out by 
Wilmot et al. (2016). In a discovery sample comprising 43 children with ADHD and 42 controls ranging 
from seven to 12 years, they identified differential DNA methylation in 95 genes, including VIPR2 (β = -
0.059). Subsequently, in a replication sample of 10 pairs of cases and controls, they confirmed DNA 
hypomethylation in one of the previously identified CpG sites in VIPR2 (cg13444538) (β = -0.096).   
Another study by Walton et al. (2017), using prospective data, reported contrasting epigenetic 
patterns in cord blood between 40 children with a chronic high vs 777 with a low trajectory of ADHD, in 
AC
CE
PT
ED
 M
AN
US
CR
IPT
15 
 
the proximity of SKI (β = -0.2), EPX (β = -0.18), PEX2 (β = 0.17), ST3GAL3 (β = -0.17), FBXW5 (β = 
0.17), ELF3 (β = 0.17), ZNF544 (β = 0.17). These epigenetic differences were no longer observable at age 
7 in whole blood. Further information on the publications investigating epigenome-wide DNA 
methylation in ADHD can be found in Table 5. 
3.3.2 Candidate Gene DNA Methylation 
The relation between candidate gene DNA methylation patterns and ADHD was analyzed in three studies 
(Adriani et al., 2017; Van Mil et al., 2014; Xu et al., 2015) in peripheral tissues only. Associations 
between differential DNA methylation and ADHD in SLC6A3/DAT1 – a gene encoding a dopamine 
transporter ([dataset] Geer et al., 2010) - were analyzed by two independent studies. Adriani et al. (2017) 
showed DNA hypomethylation of the SLC6A3 gene in 30 cases compared to 15 controls ranging from six 
to 12 years in blood and buccal tissues. In contrast, Xu et al. (2015) did not observe differential DNA 
methylation patterns in DAT1 between 50 children suffering from ADHD and 50 controls ranging from 
four to 12 years.  
Associations between differential DNA methylation and ADHD in DRD4 – a gene encoding a 
dopamine receptor ([dataset] Geer et al., 2010) - were found by two independent studies; however, the 
direction of the effect was inconsistent (Van Mil et al., 2014; Xu et al., 2015). Van Mil et al. (2014) 
reported DNA hypomethylation in DRD4 in the cord blood of children with ADHD (β = -0.52).  Xu et al. 
(2015) additionally showed DNA hypermethylation in individuals with ADHD in correspondence to 
DRD4.  
Van Mil et al. (2014) also found hypomethylation of 5-HTT in cord blood (β = -0.22). No 
evidence for significantly different epigenetic marks was identified in CpGs in, or near, IGF2, H19, 
KCNQ1OT1, MTHFR and NR3C1 (Van Mil et al., 2014). More information on the studies examining 
candidate gene DNA methylation in ADHD can be found in Table 6.  
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4. DISCUSSION  
The present work aimed to provide a comprehensive evaluation of the current evidence for the relation of 
differential epigenetic markers with ASD and ADHD. To our knowledge, this is the first systematic 
review examining epigenetic modifications in each neurodevelopmental disorder.  
Of the 29 included publications, the majority focused on DNA methylation, examined autism and 
selected a cross-sectional design. Studies used different tissues and analytical approaches. These results 
provide preliminary support for an association between epigenetic alterations and neurodevelopmental 
disorders. Yet, the mixed findings, the small-sized samples, and the low comparability of publications 
prohibit definite conclusions.  
4.1 Summary of key Findings 
Of the small set of studies investigating global DNA methylation in relation to autism, some identified 
hypermethylation in cases while others found no evidence for differences between groups. Similarly, 
mixed results have been reported in the global DNA methylation patterns of individuals affected by 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and other chronic diseases (Braun et 
al., 2016; Muka et al., 2016a; Muka et al., 2016b; Wen et al., 2016). Inconsistencies might stem from 
heterogeneity in (i) the tissues selected (e.g. blood vs brain tissue), (ii) the analytical and statistical 
methods used (e.g. differences in DNA methylation assessment methods, analytic routines and 
significance thresholds) and, (iii) the sample characteristics (e.g. age differences). Generally, hypothesis-
free approaches (EWAS) did not yield consistent results although often the same array was employed. 
Nevertheless, the identification of differential DNA methylation in the proximity of three genes – PRRT1, 
C11orf21/TSPAN32, and OR2L13 -  in multiple independent analyses, is a promising preliminary finding. 
Mutations in the gene family of PRRT1 are involved in neurological disorders such as familial infantile 
seizure (Ladd-Acosta et al., 2014). A similar role in normal/neurological phenotypes was described for the 
mice homolog prrt1, which is also implicated in central nervous system functioning ([dataset] Smith et al., 
2018). The genomic area encompassing C11orf21 and TSPAN32 could constitute a bidirectional promoter, 
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hence a DNA region in which transcriptional processes of two genes are commenced in opposite 
orientations from a putative promoter. Given the important role of bidirectional promoters in gene 
regulation and in the production of both coding and non-coding RNA (Wei et al., 2011), we speculate that 
epigenetic alterations within C11orf21/TSPAN32 might lead to pervasive effects in transcriptional 
regulation at a genome-wide level. The function of C11orf21 is yet to be elucidated, although one study 
suggested its role in cytoplasmic localization (Zhu et al., 2000). In contrast, more information is available 
for TSPAN32, which is located within the tumor-suppressor gene region encompassing chromosome 
11p15.5 ([dataset] Geer et al., 2010). DNA methylation alterations in TSPAN32 were found to relate with 
Beckwith-Wiedemann syndrome ([dataset] Geer et al., 2010), a disease characterized by genetic and 
epigenetic dysregulation ([dataset] Shuman et al., 2016; Weksberg, 2010). The increased incidence of 
autism among individuals suffering from Beckwith-Wiedemann syndrome ([dataset] Shuman et al., 2016; 
Betancur, 2011) suggests that TSPAN32 DNA methylation status might play a role in both disorders. 
Moreover, mutations in another member of the tetraspanin family, TSPAN8, were described in other 
psychiatric conditions, namely in schizophrenia and bipolar disorder (Scholz et al., 2010). OR2L13 is 
responsible for the initialization of the neuronal response to odorants (Berko et al., 2014). Mice studies 
have also observed involvement in olfactory receptor activity in the homologs of OR2L13, olfr166 and 
olfr168 ([dataset] Smith et al., 2018). Olfactory dysfunctions have been reported in autistic patients and 
were found to correlate with the social impairment component of the disorder (Bennetto et al., 2007; 
Hilton et al., 2010). DNA methylation differences in OR2L13 between cases and controls were not found 
in monozygotic twins discordant for the disorder (Wong et al., 2014), indicating the possibility of an 
influence of genetic variants on these epigenetic markers. As evident through a mQTL database search 
(Gaunt et al., 2016), the CpG of interest (cg20507276) was indeed related to numerous single nucleotide 
polymorphisms. Yet results should be interpreted with caution because of numerous caveats in the 
literature, such as the very small sample size employed and the use of platforms with lower CpG coverage 
(Infinium 27k array). A number of shared biological pathways of relevance to neurodevelopment were 
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reported by independent EWAS, including synaptic and neuronal processes (Nardone et al., 2017; Nguyen 
et al., 2010), immune response processes (Nardone et al., 2017; Nardone et al., 2014; Nguyen et al., 2010), 
brain development (Nguyen et al., 2010) and cellular differentiation (Table 2). Candidate gene studies of 
autism identified DNA methylation differences in multiple genes; however, the absence of replication 
implies that the field lacks credible data to assess how DNA methylation of specific a priori genes 
associates with autism. Histone modifications (trimethylation and acetylation) in association with ASD 
were consistently found in H3K27 in the cerebellum and cortices of autistic patients. Yet, a role of these 
variations in autism can only be inferred very cautiously due to the high reversibility and complicated 
mechanisms that histone modifications entail. 
 Associations of epigenetic patterns with ADHD were explored in a few studies only, which 
focused on site-specific DNA methylation. Overall, epigenome-wide approaches to DNA methylation 
analysis provided inconsistent findings. Nevertheless, VIPR2 was recognized as hypomethylated in two 
independent samples by Wilmot et al. (2016). Duplications and SNPs in VIPR2 seem to be implicated in 
schizophrenia and mood disorders, respectively. Vipr2 was also found to be involved in hypo-activity in 
mice models ([dataset] Smith et al., 2018). Based on this finding and on their research, Wilmot et al. 
(2016) speculated the possibility of a relation between human hyperactivity symptoms and decreased 
DNA methylation in VIPR2. Further investigations are needed. Interestingly, both VIPR2 (for ADHD) and 
OR2LI3 (for ASD) are involved in the signaling by G-protein-coupled-receptors (GPCR) pathway 
([dataset] Weizmann Institute of Science, c2018), which includes genes responsive to stimuli external to 
the cell, including odors and neurotransmitters. This might indicate that epigenetic dysregulation of the 
signaling by GPCR pathway could be characteristic of both neurodevelopmental disorders; however, it 
should be noted that only two of the 2’601 genes included in this network were observed as differentially 
methylated. Further pathways involved in ADHD shared by non-replicated sites/regions include 
peroxisomal processes and transcriptional activity (Table 5) (Wilmot et al., 2016). Candidate gene DNA 
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methylation studies of ADHD could not find consistent evidence of differential DNA methylation between 
cases and controls or did not attempt to replicate their results.  
  
4.2 Current Challenges in the Field and Recommendations for Future Research 
When interpreting the reported findings, multiple methodological issues should be acknowledged. First, 
the selected DNA methylation assessment method (global, candidate gene and genome-wide DNA 
methylation analysis) might explain reported inconsistencies (e.g. direction of DNA methylation 
differences – hypo, hyper – and lack of converging findings in epigenome-wide and candidate gene 
studies). Global DNA methylation might not be a sufficiently fine-grained method since epigenetic 
modifications in psychiatric phenotypes are likely to be subtle and site-specific compared to disorders 
characterized by large-scale genomic instability. Although epigenome-wide and candidate gene 
approaches permit a more detailed assessment of DNA methylation, these two methods diverge on several 
aspects. With the setback of higher statistical burden and costs, epigenome-wide analysis permits a wider 
coverage of the genome and the discovery of differentially methylated genes, which could otherwise be 
disregarded. A hypothesis-free approach thus appears the most appropriate when knowledge on the 
epigenetics of the disorder is limited, as in ASD and ADHD. Yet, epigenome-wide studies require more 
stringent guidelines before we can successfully identify true and consistent effects (Heijmans and Mill, 
2012). Overall, we are confident that once EWAS are more standardized and well-powered, it will be 
possible to meta-analyze findings and to detect consistent alterations in DNA methylation.  
Second, the selection of statistical analyses likely influenced the detection of differentially 
methylated patterns. The included studies mainly analyzed differentially methylated positions (site-by-site 
analysis) or regions (regional change analysis). The former consider the association of each differentially 
methylated site with the disorder of interest, while the latter provide a proportion of the methylated 
cytosines in a specific area of the gene (Mill and Heijmans, 2013). Currently, there is no consensus on the 
most appropriate statistical analysis for epigenetic studies. Combination of approaches would enable the 
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identification of single abnormally methylated CpGs (site-by-site analysis), as well as the clustering of 
correlated sites (regional analysis or other reduction-based strategies) which are likely to be functionally 
relevant. This was performed in few of the reviewed studies (Aldinger et al., 2013; Homs et al., 2016; 
Nardone et al., 2014), which exemplify the current developments in the field.  
Most of the selected publications measured differential DNA methylation patterns based on 
bisulfite-treated DNA, which involves the deamination of non-methylated cytosines to uracil while 
leaving unaltered the methylated cytosines. A major setback of bisulfite conversion is the inability to 
distinguish between 5-mC and 5-hydroxymethylcytosine (5-hmC), another form of epigenetic 
modification involving the oxidation of 5-methylcytosine (Huang et al., 2010). Profiling 5-hmC separately 
could be insightful for ASD and ADHD research, given its role in neurodevelopment and disease. For 
instance, together with TET proteins, 5-hydroxymethylcytosine is considered to be involved in the DNA 
demethylation of 5-mC occurring during epigenetic reprogramming in the developing germline or in the 
early embryonic phase (Hill et al., 2014). In line with this, developmental regulation of 5-hmC quantities, 
with an increase from early postnatal stage to adulthood, has been reported in mice brain tissue (Szulwach 
et al., 2011). Of the included studies, none distinguished 5-hmC from 5-mC, indicating that the reported 
findings might not accurately portray the DNA methylation patterns of the participants, especially in brain 
tissue where 5-hmC is enriched. The implementation of methods enabling the distinction between 5-mC 
and 5-hmC, such as oxidative bisulfite sequencing (Booth et al., 2012), could enable advancements in the 
understanding of the epigenetic processes involved in neurodevelopmental and related disorders.  
A key issue in epigenetic research and especially in the included publications is the use of small 
sample sizes. Although there are no general guidelines, Tsai and Bell (2015) estimated the minimum 
number of participants necessary to reach 80% power according to multiple factors such as the mean DNA 
methylation difference present between affected and unaffected individuals. In particular, they reported 
that EWAS should include at least 54 case-control pairs to have adequate power to detect a 15% mean 
DNA methylation difference at a genome-wide significance. With the exception of a couple of studies 
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(Homs et al., 2016; Wang et al., 2014), none of the included publications met this criterion indicating that 
most epigenome-wide analyses likely did not have the power to detect true DNA methylation differences. 
It is thus of utmost importance to consider the gathered results as preliminary and to interpret them with 
caution. It should also be noted that since mean DNA methylation differences between cases and controls 
at single CpG sites are likely to be small in effect size, much larger samples should be employed.  
The included publications were mostly comparing cases and controls cross-sectionally, meaning 
that causal inferences could not be drawn due to the presence of the disorder during assessment. 
Contrarily, a prospective design, which allows for measuring epigenetic patterns pre-symptom onset, 
could elucidate the direction of the epigenetics-disorder relation. Monozygotic-twin discordant studies are 
another substantial resource as they control for the influence of genetic variants and display DNA 
methylation changes arising from discordant environmental exposures. The results stemming from both 
monozygotic-twin discordant and longitudinal designs should be integrated to identify the direction of the 
epigenetics – disorder relation (longitudinal design), as well as the influence of genetic variants on 
epigenetic markers (twin-discordant study). The use of repeated measurements in longitudinal studies 
would provide further insight, as exemplified by Walton et al. (2017), whose results varied with age of the 
children.  
Regardless of the design, findings can be hampered by confounding variables influencing the 
association between DNA methylation and symptomatology of the disorder and causing inflated and 
inaccurate results. Although the majority of the included publications corrected for potential third 
variables, among which sex and age were the most common, adjustments for technical covariates such as 
batch effects and cell type were performed by a few studies only (e.g. Berko et al., 2014; Nardone et al., 
2017).  
The included publications mainly examined brain and blood. Because of epigenetic tissue 
specificity (i.e. each tissue has its specific epigenetic patterns), peripheral tissues may not be appropriate 
surrogates to estimate alterations in the brain of individuals affected by neurodevelopmental disorders. 
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Yet, modifications of early development might present higher inter-tissue concordance (Heijmans and 
Mill, 2012). The brain may be the most suitable source for the identification of disease biomarkers 
(Bakulski et al., 2016), but its analysis can be problematic and highly impractical due to limited 
availability of post-mortem data, the impossibility to infer causality, and degeneration of the genetic 
material (Wen et al., 2016). In addition, as epigenetic marks can change across the lifetime (Bell and 
Spector, 2011), modifications measured after patients’ death may not be representative of the ones present 
during disorder onset or course. Peripheral blood is easier to access and can be collected at any age, it 
enables analysis of larger samples and can be examined longitudinally (Bakulski et al., 2016). 
Interestingly, Smith et al. (2015) suggested saliva as a more appropriate peripheral tissue than blood, due 
to its greater similarity to brain tissue. Importantly, since we are unaware of whether neurodevelopmental 
disorders depend on DNA methylation variations in the brain only or in multiple tissues, we suggest the 
analysis of different tissue types. When this approach is not feasible, consulting online resources showing 
correlations between peripheral tissues and brain is advised. Moreover, focusing on the use and 
development of non-invasive techniques for in vivo brain analysis, such as brain imaging, is of importance 
(Rakyan et al., 2011).  
Epigenetic patterns not only vary across tissues, but also within tissues as these contain a mixture 
of cell types such as leucocytes and red blood cells in whole blood or neurons and glial cells in brain. 
Failure to account for such heterogeneity can severely confound results. For instance, if cases and controls 
diverge in their cell-type proportions, observed epigenetic differences might reflect cell-type composition 
rather than the phenotype of interest (Bock, 2012; Rakyan et al., 2011). The methods commonly employed 
to address cellular heterogeneity include cell sorting, reference-based (e.g. Houseman’s constrained 
projection) and reference-free methods (e.g. RefFreeEWAS). Cell sorting provides the exact proportion of 
different cell types in a specific sample but is more costly and labor-intensive than the alternatives. 
Reference-based and reference-free methods, estimating cell-type composition with algorithms 
(Teschendorff and Zheng, 2017), provide a more feasible yet less accurate option. Of the reviewed studies, 
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only a minority corrected for cell-type heterogeneity. Most publications used reference-based methods, a 
few studies selected histologically identical cells, purified cells or reference-free methods, and two 
employed cell sorting (Nardone et al., 2017; Wong et al., 2014). Given the importance of accounting for 
cellular heterogeneity, Birney et al. (2016) suggested analyzing purified or histologically identical cells 
together with using any mean available to quantify cell-type proportions. 
In the reviewed studies, epigenetic findings tended to be solely based on statistical significance. It 
is however unclear to what extent statistically significant CpGs/regions reflect a functional effect (i.e. 
variation in the phenotype). In order to solve this issue, Barker et al. (2017) proposed the integration of 
DNA methylation data with other omics (e.g. proteomics), the use of animal models and of in vitro 
experiments. Several studies conducted gene expression or gene set enrichment analyses and could thus 
bridge the gap between statistical and functional significance (e.g. Aldinger et al., 2013; Ginsberg et al., 
2012). 
The limited understanding of the role of epigenetics in mental health disorders constitutes another 
key challenge in this field.  Epigenetic modifications could exert a causal role in disorder etiology by 
mediating or modifying genetic or environmental risk or by representing the biological mechanism for 
gene-environment interactions (Ladd-Acosta and Fallin, 2016). Conversely, if not pathways to disorder 
onset, epigenetic alterations could be biomarkers of exposure to environmental factors or to the disorder 
itself. If epigenetics mediates the relation between environment and disorder, scientists might be able to 
help reverse psychiatric conditions by altering nutrition, behavior, social factors, and with the use of drugs 
(Rutten and Mill, 2009). On the other hand, improvements in the accuracy of diagnoses and of illness 
detection could be achieved in case epigenetic modifications are biomarkers of disease (Ladd-Acosta and 
Fallin, 2016). Characterizing the role of epigenetics with respect to disorder, environment, and genotype 
would greatly contribute to moving the field forward, enabling appropriate interpretation of epigenetic 
findings and informing potential translational applications for public health.  
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In conclusion, current evidence suggests the possibility of an association between epigenetic 
modifications and neurodevelopmental disorders. Yet, with very few exceptions, the results were either 
conflicting or not independently replicated. The available research is limited and hampered by small 
samples, suboptimal designs and heterogeneity in approaches, analyses and tissues. While scientists are 
still far from understanding the causal, diagnostic or prognostic role of epigenetics in neurodevelopmental 
disorders, this field is exciting due to its rapid development and advances. Longitudinal and genetically-
sensitive designs, increased samples sizes, adjustments for appropriate confounders and integration of 
omics-data will permit the delineation of the role of this promising field in ASD and ADHD. Careful 
investigations of epigenetic processes in relation to these and other neurodevelopmental disorders are 
highly recommended.   
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Figure captions: 
Figure 1. PRISMA flow diagram of the studies included in this systematic review. 
Of the 2174 retrieved articles, after deduplication, we screened the title and/or abstract of 2169 
publications and identified 86 potentially relevant ones. Based on a full-text assessment of their eligibility, 
29 publications were included in this systematic review. Abbreviations: n=number.   
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Table 1.  
Global DNA methylation and Autism Spectrum Disorder. 
Author Cases 
/Controls 
 
Sample 
Characteristics 
Tissue Adjustments/Matching Method Findings Significance 
Level 
Brain tissue  
James et al. 
(2013) 
 13/13 from 
2 samples 
  
USA  
4-30 y. 
M and F 
CB Matched by age, sex, race, PMI and cause 
of death. 
LC-MS/MS Hypermethylation (5.9±1.2 in ASD 
patients, 4.7±1.1 in controls).  
p < 0.05 
Mitchell et 
al. (2012) 
 
 12/12  USA  
4-61 y. 
M and F 
BA19 Sex, birth period, brain region /age and sex. LINE-1 No significant differences.  p < 0.05 
Peripheral tissue  
Schroeder et 
al. (2016) 
 24/23 
   
USA 
Birth to 36m. 
M and F 
 
Placenta, CBL 
and non-
specified 
Sex, sequencing run number, order of 
sequencing, average sequencing coverage / 
sex and birth year.  
MethylC-
sequencing 
No significant differences. FDR < 0.05 
Tsang et al. 
(2016) 
 
 280/236 
  
China 
MASD = 4.7 y. 
Mcontrols=5.3 y. 
M and F 
 
Leukocytes Matched by age. HpaII/MspI Hypermethylation (∆β = 
54.35±21.37) in autistic subjects.  
p < 0.05 
Wong et al. 
(2014) 
 
 66/44 
 
 
UK 
Birth to 15y. 
sex NA 
 
WB Adjusted for blood cell count. LUMA No significant differences (M = 
65.1% in autistic twin, M = 65.9% 
in unaffected twin). 
p < 0.82 (based on 
observed p-value) 
ASD = Autism Spectrum Disorder; BA   Brodmann’s Area; CB = cerebellum; CBL = cord blood; F = females; FDR = false discovery rate; M = males; m. = months; NA = not available; PMI = post-
mortem interval; WB = whole blood; y. = years. 
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Table 2.  
Epigenome-wide DNA methylation and Autism Spectrum Disorder.  
Author Cases  
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analysis 
Platform Replication 
Validation 
Adjustments  
/Matching 
Findings Significance 
Level 
Brain tissue  
Feinberg 
et al. 
(2015) 
 
19/21 
  
NA FC, TC, CB DMR  Infinium 
450k array  
None None Differential DNA methylation in 
SNORD family genes in CB, in 
12 regions in FC and 10 regions 
in TC.  
p < 0.05  
Ginsberg 
et al. 
(2012) 
 
17/17 from 
2 samples 
  
USA, UK, Canada 
and unknown 
1-60 y. 
M 
BA19 and 
cerebellar 
hemispheric 
cortex. 
 
DMP  Infinium 
27k array 
None Region and age / 
age and sex. 
No significant differences.  
 
 
FDR ≤ 0.05 and 
FDR ≤ 0.25 
Ladd-
Acosta et 
al. (2014) 
20/21 from 
3 samples 
USA 
NA 
TC, PFC, CB DMR Infinium 
450k array 
Replication, 25/26 Sex, cell type / age, 
sex and PMI 
DNA hypomethylation in cases in 
PRRT1 (∆M = -7.8%.), 
C11orf21/TSPAN32 (∆M = -
6.6%) and DNA 
hypermethylation in ZFP57 (∆M 
= 13.9%) in cases in TC. DNA 
hypermethylation in SDHAP3 in 
cases in cerebellum (∆M = 
15.8%).  
Differential DNA methylation 
replicated in the same regions 
encompassing PRRT1 and 
C11orf21/TSPAN32. 
NB: Replication analyses were 
conducted in a different brain 
tissue of the same individuals in 
DMR: FWER ≤ 
0.1 
Replication: p < 
0.05 
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Author Cases  
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analysis 
Platform Replication 
Validation 
Adjustments  
/Matching 
Findings Significance 
Level 
the discovery cohort.  
Nardone 
et al. 
(2017) 
15/16 from 
2 samples 
  
UK, USA 
17-68 y. 
M 
 
PFC, BA10, 
BA9, BA8 
DMR        
DMP 
Infinium 
450k array 
Validation with 
NGBS 
Technical and 
biological 
covariates / age, 
brain mass and 
PMI  
No significant differential DNA 
methylation in DMP analysis. 
Differential DNA methylation in 
58 regions, spanning GABBR1, 
ABAT, Mir124-1, Mir124-2 in 
DMR analysis  
DNA hypomethylation in 
GABBR1 and Mir124-2 and DNA 
hypermethylation in FAM124B 
and InNEAT1 in cases validated.  
Pathways: synaptic and neuronal 
processes and immune response 
processes. 
DMP and DMR: 
FDR < 0.05 
Validation: p < 
0.05 
Nardone 
et al. 
(2014) 
 
24/23 from 
2 samples 
  
UK, USA 
16-51 y. 
M and F 
BA10, BA24 DMP Infinium 
450k array  
 
Validation with 
pyrosequencing 
Adjusted for sex 
and batch effects 
Differential DNA methylation in 
5329 CpGs in BA10 and 10745 in 
BA24, including HDAC4, 
PRRT1, C11orf21/TSPAN32, 
C1qA, IRF8, CTSZ. 
DNA hypomethylation of 
C11orf21 (∆β = 0.39 to -4.93) 
and C1qA (∆β = -3.45), IRF8 (∆β 
= -3.42), CTSZ (∆β = -2.13 to -
3.39) in BA10 in cases validated.  
Pathways: immune responses, 
neuron-neuron synaptic 
transmission.    
DMP: FDR < 
0.05 
Validation: p < 
0.06 (based on 
observed p-
values) 
Peripheral tissue  
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Author Cases  
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analysis 
Platform Replication 
Validation 
Adjustments  
/Matching 
Findings Significance 
Level 
Aldinger 
et al. 
(2013) 
 
4/6 
  
USA 
Age NA 
F 
LCL DMP and 
grouping of 
CpG sites  
 
Infinium 
27k array 
Replication in 
13/13.     
Validation with 
MassArray 
EpiTYPER.  
Matched by age Differential methylation in 261 
probes (|∆β| > 0.15), including 
probes in PTCD2, TAC1, 
HOXA11, TCN1, ETNK2.  
Results not replicated.  
Differential DNA methylation in 
PTCD2, FLJ44881, SPAG7, 
TAC1 in the pooled analysis. 
TAC1 validated. .  
 
DMP: p < 0.01, 
FDR < 0.10 
Replication and 
pooled: p < 
0.0005 
Validation: p < 
0.005 
Berko et 
al. (2014) 
 
47/48 
  
USA 
1-28 y. 
M and F 
Buccal tissue DMR Infinium 
450k array  
 
Validation with 
NGBS 
Adjustment for sex, 
age, ancestry, 
SNPs, technical 
variables, ASD 
status, microarray-
based variables and 
batch effects 
 
Differential DNA methylation in 
13 genes: OR2L13(β = -8.0%), 
PAX8 (β = -7.5%), GPC1 (β = -
8.6%), ADRA2C (β = -11.9%), 
FAM134B (β = -7.8%), CREB5 (β 
= 7.6%), NOS1 (β = 8.6%), 
MAPK8IP3 (β = 9%), HOOK2 (β 
= -7.9%), NRG2 (β = 7.6%), 
KCNQ5 (β = 7.7%), ZG16B (β = 
10.1%), LOC643802 (β = -8.9%).  
OR2L13 validated as 
hypomethylated.  
 
DMP:1-log10 
(based on 
observed values 
for FAM134B, 
ORL13) or 
unclear (for other 
genes). 
Validation: p < 
0.05 
Homs et 
al. (2016) 
 
53/757 
from 4 
samples 
  
Spain, USA and 
other Europeans 
Age 2-101 
M and F 
PB, CBL, 
WB 
DMP, DMR 
and individual 
analysis (each 
single case 
compared to 
10 controls) 
Infinium 
450k array 
Replication in 
415/405.  
Validation with 
Sanger BS and 
pyrosequencing.  
Matched by age in 
one sample.  
No significant differences in 
DMP analysis. Differential DNA 
methylation in DMR analysis in 
five regions in four patients only. 
Differential DNA methylation in 
700 CpGs in the individual 
analysis due to rare genetic 
variants.  
Differential DNA methylation in 
individual analysis replicated in 
DMP: q ≤ 0.01. 
DMR: p < 0.01 
Individual 
analysis:p < 0.01, 
f < 0.005 
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Author Cases  
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analysis 
Platform Replication 
Validation 
Adjustments  
/Matching 
Findings Significance 
Level 
17/700 CpGs. Differential DNA 
methylation in DMR validated.  
Pathways: AMP-activated protein 
kinase signaling.  
Nguyen et 
al. (2010) 
 
5/9 
 
USA 
2-19y 
M 
LCL DMP MIRA Validation with 
MSP or Sanger 
BS  
None Differential DNA methylation in 
73 CpG islands between 
discordant monozygotic twins. 
Differential DNA methylation in 
201 CpG islands when comparing 
both twins to unaffected siblings. 
DNA hypermethylation in BCL-2 
(M = ~25% in ASD, M = 9.5% in 
controls) and RORA in cases. 
Results were validated.  
Pathways: inflammation and 
apoptosis, brain morphogenesis, 
cellular differentiation, growth 
rate, myelination, cytokine 
production, synaptic regulation, 
steroid biosynthesis, learning.  
DMP: log2 -
0.938 (based on 
observed values) 
Validation: not 
reported. 
Schroeder 
et al. 
(2016) 
 
24/23 
 
USA 
Birth to 36m. 
M and F 
 
Placenta Grouping of 
CpG sites 
WGBS Validation with 
pyrosequencing 
Sequencing run, 
order, coverage, 
child ethnicity, sex 
/ sex and birth-
year. 
DNA hypermethylation near 
DLL1 and LOC15444 in cases.  
Results were validated.  
Grouping of CpG 
sites: FDR ≤ 0.05 
Validation: p < 
0.05.  
Wang et 
al. (2014) 
 
5/5 
  
China 
3-12y. 
M and F 
Venous B DMR 
(promoters 
and CpG 
islands)  
MeDIP Replication, 
131/131 
Validation with 
Sanger BS 
Matched by age 
and sex. 
Differential DNA methylation in 
228 gene promoters and 247 CpG 
islands when comparing 5 cases 
and 5 controls.  
DNA hypermethylation in ENO2 
promoter replicated in 15% of the 
replication sample (M = 39.1% in 
autistic patients, M = 18.81% in 
controls). 
DMR: p < 0.05 
Replication: p < 
0.01 
Validation: p < 
0.01 
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Author Cases  
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analysis 
Platform Replication 
Validation 
Adjustments  
/Matching 
Findings Significance 
Level 
Wong et 
al. (2014) 
 
66/44 
 
 
 
 
UK 
Birth to 15y. 
M and F 
 
WB DMP (one for 
discordant 
twins, one for 
cases vs. 
controls) 
Infinium 
27k array 
Validation with 
pyrosequencing 
Adjusted for cell 
count. 
DNA hypomethylation in the 
promoter of PIK3C3 in affected 
twins (∆β = -0.04) in DMR. DNA 
hypomethylation in NFYC in 
affected twin in DMP analysis. 
Differential DNA methylation in 
MGC3207(∆β = -0.24), 
OR2L13(∆β = 0.18) and 
C14orf152(∆β = -0.16) between 
cases and controls.  
OR2L13 (r = 0.86) and 
MGC3207 (r = 0.91) validated.   
DMP (twins): p < 
0.018 (based on 
observed p-
values for top 50 
hits) 
DMP (cases-
controls): p < 
0.00062 (based 
on observed p-
values for top 50 
hits) 
Validation: not 
reported. 
ASD = Autism Spectrum Disorder; B = blood; BA = Brodmann’s Area; CB = cerebellum; CBL = cord blood; DMP = differentially methylated positions; DMR = differentially methylated regions; F = 
females; FC = frontal cortex; FDR = false discovery rate; FWER = familywise error rate; LCL = lymphoblastoid cell lines; M = males; NA = not available; PB = peripheral blood; PFC = prefrontal 
cortex; PMI = post-mortem interval;  = TC = temporal cortex; WB =  whole blood; WGCNA = weighted gene co-expression network analysis; y.  = years.
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Table 3.  
Candidate gene DNA methylation and Autism Spectrum Disorder.  
Author Cases 
/Controls 
Sample 
Characteristics 
Tissue Gene Statistical 
Analysis 
Platform Adjustments 
/Matching 
Findings Significance 
Level  
Brain tissue  
Ginsberg et 
al. (2012) 
 
>7/>7 
  
USA, UK, 
Canada and 
unknown 
1-60 y.  
M 
BA19 and 
cerebellar 
hemispheric 
cortex. 
 
RORA, BCL2, 
UBE3A, 
MECP2, OXTR, 
CEBPD 
DMP Pyrosequencing Matched by age 
and sex.  
No significant differences.  FWER ≤ 0.05 
James et al. 
(2013) 
13/13 
from 2 
samples 
  
USA 
4-30 y. 
M and F 
CB EN-2 (promoter) DMP  Restriction 
enzymes   
Matched by age, 
sex, PMI, cause 
of death and 
race.  
DNA hypermethylation in autistic 
patients in all restriction enzymes used 
(McrBC-PCR analysis:23±4% of 
DNA methylation in ASD, 10±2% of 
DNA methylation in controls); (MSR-
PCR :38±7% in ASD, 15±5% in 
controls). 
 
p < 0.05 
Jiang et al. 
(2004) 
17/60 
from 3 
samples 
  
NA 
 
CB, CC SNRPN 5’-end, 
UBE3A (3’and 
5’-end) 
DMR Restriction 
enzymes 
None Differential DNA methylation in one 
participant in UBE3A. 
NB: This was the only candidate gene 
DNA methylation study performing 
validation (Sanger BS).  
Not reported 
Lintas et al. 
(2016) 
6/6 from 3 
samples 
  
USA 
16-30 y. 
10M and 2F 
BA41/42, 
BA22 
RELN 
(promoter) 
DMR Sanger BS Matched by age, 
sex and PMI. 
Differential DNA methylation 
distribution. Hypermethylation in the 
5’ portion in autistic subjects 
(29.55±13.09 in cases, 5.70±2.90 in 
controls). 
p < 0.05 
Mitchell et 
al. (2012) 
12/12 
  
USA 
4-61 y. 
M and F 
BA19 OCA2 
(promoter) 
DMP  Pyrosequencing Sex, birth period, 
brain region/ age 
and sex 
No significant differences.  
 
 
 
p < 0.05 
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Author Cases 
/Controls 
Sample 
Characteristics 
Tissue Gene Statistical 
Analysis 
Platform Adjustments 
/Matching 
Findings Significance 
Level  
Nagarajan 
et al. 
(2008) 
9/9 from 4 
samples 
  
USA 
2-21 y. 
M and F 
BA9 MECP2 
(promoter region 
II) 
DMR Sanger BS Matched by age, 
sex and 
geographical 
area. 
No significant differences. 
 
 
p < 0.07 
(based on 
observed p-
value) 
Nagarajan 
et al. 
(2006) 
20/27 
from 4 
samples 
  
USA 
76days – 57 y. 
32M  
BA9, FG MECP2 
(promoter region 
I) 
DMR Sanger BS None DNA hypermethylation in autistic 
subjects.  
NB: Site 3 of region I is the only site 
of MeCP2 showing a statistically 
significant higher DNA methylation in 
cases than controls.  
 
p < 0.05. 
Peripheral tissue  
Atsem et 
al. (2016) 
74/41 
from 3 
samples 
  
France, Germany 
2-20y.  
M 
B FOXK1 DMR NGBS Age/age and sex No significant differences. 
 
 
 
Not reported.  
Bonora et 
al. (2002) 
 
46/10 
  
 
Consortium 
NA 
L PEG1/MEST, 
COPG2 (CpG 
islands) 
DMR  Restriction 
enzymes 
None No significant differences.  Not reported.  
Delgado et 
al. (2014) 
86/48 
  
Spain 
Age and sex NA 
PB PEG13, KCNK9, 
TRAPPC9  
DMR Pyrosequencing None No significant differences. Not reported 
Hranilovic 
et al. 
(2016) 
90/66 
  
Croatia 
4-60 y. 
M and F 
L HTR2A 
(promoter) 
DMR  Sanger BS Age, sex and 
genotype/ age 
and genotype 
DNA hypermethylation in the AG 
subgroup of autistic patients. No 
significant differences for the AA and 
GG subgroups.  
Adjusted p ≤ 
0.05 
ASD = Autism Spectrum Disorder; B = blood; BA = Brodmann’s Area; CB = cerebellum; CC = cerebral cortex; DMP = differentially methylated positions; DMR = differentially methylated regions; F 
= females; FG = fusiform gyrus; FWER = familywise error rate; L = leucocytes; M = males; NA = not available; NB = nota bene; PB = peripheral blood; PMI = post-mortem interval; RBC = red blood 
cells; y. = years. 
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Table 4.  
Histone modifications and Autism Spectrum Disorder.  
Author Cases/Controls 
 
Sample 
Characteristics 
Tissue Histone and 
Lysine 
Adjustments/Matching Findings Significance 
Level 
         
James et al. 
(2013) 
11/11 
  
USA 
4-30y. 
M and F 
CB H3K27 
H3K4 
Matched by age, sex, race, cause of death 
and PMI.   
H3K27 trimethylation levels decreased in ASD 
individuals. No significant trymethylation 
differences in H3K4. 
 
p < 0.05 
Sun et al. 
(2016) 
45/49 
  
 
 
Consortium 
10-81 y. 
M and F 
PFC, 
TC, CB 
H3K27 Adjusted for sex, age, proportion of 
neurons, multiple technical covariates. 
Differential acetylation in cortices and cerebellum.   
 
q ≤ 0.05 
ASD = Autism Spectrum Disorder; CB = cerebellum; F = females; H = histone; K = lysine; M = males; PFC = prefrontal cortex; PMI = post-mortem interval; TC = temporal cortex; y. = years. 
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Table 5. 
Epigenome-wide DNA methylation and Attention-Deficit/Hyperactivity Disorder.  
ADHD = Attention-Deficit/Hyperactivity Disorder; CBL = cord blood; DMP = differentially methylated positions; F = females; FDR = false discovery rate; M = males; NB = nota bene; y.= years. 
 
Author Cases 
/Controls 
 
Sample 
Characteristics 
Tissue Statistical 
Analyses 
Platform Replication 
Validation 
Adjustments/ 
Matching 
Findings Significance 
Level 
Walton et 
al. (2017) 
 
Birth: 
40/777 
7y.: 50/842 
UK 
Birth to 15 y. 
M and F 
CBL and 
other 
peripheral 
tissues 
 
DMP Infinium 
450k array 
None Adjusted for sex, 
chip and cell type, 
batch effects. 
Differential DNA methylation in SKI 
(β = -0.2), EPX (β = -0.18), PEX2 (β 
= 0.17), ST3GAL3 (β = -0.17), 
FBXW5 (β = 0.17), ELF3 (β = 0.17), 
ZNF544 (β = 0.17) at birth. No 
significant differences at age 7.  
NB This is the only study employing 
multiple measurements of DNA 
methylation.  
  
q < 0.05 
Wilmot 
et al. 
(2016) 
43/42 
 
USA 
7-11.8 y. 
M 
Saliva DMP Infinium 
450k array 
Replication in 
10/10        
Validation with 
NGBS 
 
Medication status, 
age, race and 
correlation among 
genes/age 
Differential DNA methylation in 95 
genes including VIPR2 (probe 
cg13444538) (β = -0.059). 
DNA hypomethylation in VIPR2 
replicated (β = -0.096) in ADHD 
subjects. DNA hypomethylation of 
43 CpG sites validated in ADHD 
patients.  
Pathways: peroxisomal processes and 
transcriptional activity.  
Discovery: ∆β > 
2%, p < 0.05 
Replication and 
validation: FDR 
< 0.05 
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Table 6.  
Candidate gene DNA methylation and Attention-Deficit/Hyperactivity Disorder.  
Author Cases 
/Controls 
Sample 
Characteristics 
Tissue Gene Statistical 
Analysis 
Platform Adjustments                   
/Matching 
Findings  Significance 
Level 
Adriani 
et al. 
(2017) 
30/15 
  
Italy 
6-14 y. 
M and F 
B and 
buccal 
tissues 
SLC6A3 (6 CpG 
sites)  
DMP Pyrosequencing None 
DNA hypomethylation 
in all six sites in all 
ADHD patients. CpGs 
at position M1 
significantly correlated 
with index scores for 
ADHD severity.    
p<0.05 or 
0.10 < p < 
0.05 
Van Mil 
et al. 
(2014) 
92/334 
 
The Netherlands 
Birth to 6 y.  
M and F  
CBL  5-HTT, DRD4, 
IGF2DMR, H19, 
KCNQ1OT1, 
MTHFR, NR3C1 
DMR 
(CpG 
islands) 
MassARRAY 
EpiTYPER 
Adjusted for maternal education, 
age, prenatal smoking, parity, use 
of alcohol, folic acid supplement 
use, child national origin, height 
and weight, BMI, batch effects and 
psychological problems, child sex, 
Apgar score (one minute after 
birth), birth weight, mode of 
delivery, gestational age at birth, 
genetic ancestry, at birth, 
psychological problems comorbid 
with ADHD and genotype.   
 
DNA hypomethylation 
in 5-HTT region B (β=-
0.22) and in the DRD4 
region (β=-0.52) when 
higher presence of 
symptoms in ADHD.  
p < 0.003 
(based on 
observed p-
values) 
Xu et 
al. 
(2015) 
50/50 
  
China 
4-12 y. 
M and F 
B DRD4, 
DAT1(promoters) 
DMP and 
DMR 
(CpG 
island) 
Sanger BS Child and parental characteristics/ 
age, sex and SES. 
 DNA hypermethylation 
in site 1 of DRD4. No 
significant differences 
in DAT1.  
 
p < 0.05 
ADHD=Attention-Deficit/Hyperactivity Disorder; B=blood; BMI= body mass index; CBL=cord blood; DMP=differentially methylated positions; DMR=differentially methylated regions; F=females; 
M=males; SES=socio-economic status; y=year 
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